Kopran Limited (NSE:KOPRAN)

India · Delayed Price · Currency is INR

194.01

+9.23 (5.00%)

Jun 19, 2026, 3:29 PM IST

1.85% (1Y)

Market Cap	9.40B +6.5%
Revenue (ttm)	6.81B +8.2%
Net Income	257.31M -33.3%
EPS	5.33 -33.2%
Shares Out	n/a
PE Ratio	36.52
Forward PE	n/a
Dividend	3.00 (1.66%)
Ex-Dividend Date	Sep 4, 2025

Volume	170,382
Open	187.00
Previous Close	184.78
Day's Range	187.00 - 194.01
52-Week Range	107.00 - 219.00
Beta	0.84
Analysts	Strong Buy
Price Target	74.00 (-61.86%)
Earnings Date	Aug 10, 2026

About Kopran

Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti- helminthics, anti-acne, anti-infective, anti-thrombotic, s... [Read more]

Industry Drug Manufacturers - General

Sector Healthcare

Founded 1958

Employees 1,024

Stock Exchange National Stock Exchange of India

Ticker Symbol KOPRAN

Full Company Profile

Financial Performance

In fiscal year 2026, Kopran's revenue was 6.81 billion, an increase of 8.23% compared to the previous year's 6.30 billion. Earnings were 257.31 million, a decrease of -33.26%.

Financial Statements